Respiratory diseases will become the third leading cause of death in 2020 according to WHO, due to pollution and tobacco. The Rheomuco device developed by Rheonova is aimed at researchers and health professionals. It helps the evaluation of treatments and the personalized, preventive and predictive monitoring of patients with cystic fibrosis, chronic bronchitis (COPD), … by measuring the viscoelastic properties of pulmonary secretions. The i-LAB grant will allow the passage of regulatory milestones, including funding a second Rheomuco clinical study. This i-LAB national grant was born from the will of the Ministry of Higher Education, Research and Innovation. The marketing of the first Rheomuco devices dedicated to academic and private research (biotech and pharma) started in 2017, and two recruitments are underway to strengthen the team.
